Race Oncology Ltd (ASX:RAC) CEO Damian Clarke-Bruce tells Proactive that they will shortly start assessing the cardiovascular-protective properties of Zantrene® (bisantrene) treatment in the observational stage of a Phase 1/2b clinical trial in breast cancer patients treated with doxorubicin and cyclophosphamide with at least two cardiovascular risk factors. Resolutum Global, Beyond Drug Development and NSW Regional Biospecimen & Research Services have been appointed to support the clinical program.
Race Oncology poised for observational heart protection breast cancer trial
